Dr. Hans-Christian Kolberg on Safer Chemotherapy for Patients with HER2-positive Early Breast Cancer
Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.
Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.
Holberg points out that the neoadjuvant chemotherapy regimen is beneficial for patients with HER2-positive early breast cancer because the toxicity is reversible. Stronger regimens with potentially greater toxicities should be saved for later use, should the patient experiences progression, he adds.
Vidal Discusses Differences in Duration and AEs With Adjuvant CDK4/6i in Breast Cancer
May 13th 2025During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.
Read More
